All stock reports

PANACEABIO evidence report

Evidence date: 2026-10-01. Research observations only.

What can I do with this stock?

Evaluated 2026-10-02T01:37:53.224812+00:00. Closed-session evidence: 2026-10-01. This is a timestamped assessment, not a live trading feed.

Strategy evidence, instrument feasibility and portfolio suitability are separate. Portfolio suitability has not been assessed.

Today: intraday

Evidence unavailable

No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

  • No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

Next week: five trading sessions

No qualifying opportunity

No candidate with a primary five-session horizon in the coherent source run.

  • No candidate with a primary five-session horizon in the coherent source run.

Long term: one to three years

Research only

A financial screen alone does not establish an investment recommendation.

  • Financial data quality flags require resolution.
  • A current, source-backed thesis and valuation review is required.

Investment evidence

Statement coverage
FULL_STATEMENTS
Financial source retrieved
2026-09-25T14:01:07.176647+00:00

Metrics

latest_annual_period
2026-03-31
revenue
6397700000.0
net_income
-53700000.0
operating_cash_flow
173400000.0
free_cash_flow
-367500000.0
total_assets
12621700000.0
total_liabilities
4332900000.0
total_equity
8348400000.0
cash
643700000.0
total_debt
236600000.0
revenue_growth
0.14430592570069223
earnings_growth
-0.3584229390681004
net_margin
-0.00839364146490145
roe
-0.0064323702745436254
debt_to_equity
0.02834075990608979
cash_conversion
-3.2290502793296088
free_cash_flow_margin
-0.057442518405051816
trailing_pe
Not supplied
forward_pe
Not supplied
peg_ratio
Not supplied
price_to_book
Not supplied
dividend_yield
Not supplied

Other positional research

Research only

1 opportunity assessments; compare evidence and conditions below.

Price Dislocation

Research only. Direction: LONG.

Flags large price dislocations for research without asserting unsupported fundamental quality

  • No active, unexpired validation authority for this exact strategy and horizon.
  • A source-backed entry, invalidation, exit and cost plan is not supplied.
Eligible expression
None selected
Expression comparison
No eligible instrument selected.
Invalidation
Continued price deterioration or adverse fundamental evidence
Entry rule
Not supplied
Entry range (INR)
Not supplied
Exit / review rule
Not supplied
Planned exit
Not supplied
Plan valid until
Not supplied
Promotion reference
Not supplied
Instrument scenarios in INR; quantities are illustrative, not personal sizing
InstrumentEvidence statusContractQuantityCapital / marginTarget P&L after costsStop-level scenario P&LStress lossConditions and limitations
NO_POSITIONAvailableNot suppliedNot suppliedNot supplied0.000.00Not suppliedNo new position; incremental trading P&L is zero.
CASHUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
FUTURESUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
OPTIONSUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
  • No reader capital or loss budget supplied
Decision provenance and limitations
Decision ID
decision-7e134809f65ef46111dd28c7a4d95d91f581d186e7cc9dd6a59e422067cb5a25
Policy
stock-decisions-v1
Evidence bundle hash
00d002a637b5510c090cfd8aa0dd442c317b27897bc35162fa1646d86d34d586
  • market-brief: a7de4d64fedac164d48cdfb9b4081a4666d7f797f7d9c58da304b329b3a61d3c
  • validation-registry: b1069587129bfc64a703cdf8322d0294692585b7d67f5472593e4164bbb0c3bc
  • financial-statements: 37b69010deeca7acebc6f7b7369f7c50d79524aa472cf390617140c70ff4e825
  • daily-price: b9999d7b706e004715d2b4d3ebc25d877456775abd91f2a2640a386ac3871b4b
  • Conditional research decisions are not orders or personalized position sizes.
  • Scenario payoffs are assumptions, not probabilities or expected returns.
  • A stop price does not guarantee a maximum loss through a gap or illiquidity.

Download the decision evidence as JSON

Evidence briefing

The local language model selected and grouped the following supplied facts.

Overview

Price source verification: REPAIRED. The cached closing price on 2026-10-01 was INR 359.05. The trailing 5-session price return was -4.19%. The trailing 20-session price return was -6.09%. The trailing 60-session price return was -31.93%. The trailing 250-session price return was -11.27%.

Risks

The closing price was -40.92% below its highest close in the available trailing year. The cached financial metric net margin is -0.00839364146490145. The cached financial metric roe is -0.0064323702745436254. The cached financial metric cash conversion is -3.2290502793296088. Financial data check: weak_cash_conversion: operating cash flow/net income below 0.5. The cached financial metric free cash flow margin is -0.057442518405051816.

Follow Up

The cached financial metric latest annual period is 2026-03-31. The cached financial metric revenue growth is 0.14430592570069223. Average cached traded value over twenty sessions was INR 34,295,452. Fundamental coverage is FULL_STATEMENTS; retrieved 2026-09-25T14:01:07.176647+00:00 from EODHD.

Cached observations and evidence limits